A shortage of funding or not enough healthcare projects?
<img src=" https://s3.amazonaws.com/production.scholastica/article/124008/large/lou.jpg?1727462674"> The author, having worked in pharmaceuticals for several decades, has advised, in confidence, both investors and small to medium-sized enterprises on transitioning healthcare research...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Andover House Inc.
2024-09-01
|
| Series: | Precision Nanomedicine |
| Online Access: | https://doi.org/10.33218/001c.124008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <img src=" https://s3.amazonaws.com/production.scholastica/article/124008/large/lou.jpg?1727462674">
The author, having worked in pharmaceuticals for several decades, has advised, in confidence, both investors and small to medium-sized enterprises on transitioning healthcare research projects into commercial development, mainly in Europe. He is now semi-retired. This note is written in the hope that his experience will improve the success of small and medium-sized enter-prises in their attempts to get non-academic investment funding and make life easier for investors. Whilst focused on drugs, the broader advice is relevant to other healthcare areas, such as diagnostics and devices. |
|---|---|
| ISSN: | 2639-9431 |